Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer By Ogkologos - April 7, 2026 132 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POLAR study Source RELATED ARTICLESMORE FROM AUTHOR High HPV Vaccination Coverage in England Associated with a Substantial Reduction in Cervical Cancer Mortality FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions MOST POPULAR FDA Approves Lazertinib with Amivantamab-vmjw for Locally Advanced or Metastatic NSCLC... September 9, 2024 Pembrolizumab Combined with Chemoradiotherapy Improves PFS in Women with Newly Diagnosed,... March 27, 2024 Finding New Uses for Targeted Therapies for Cancer: Updates from the... November 9, 2023 Firefighter Advocates For Men’s Health While He Battles Breast Cancer In... September 22, 2021 Load more HOT NEWS Woman Diagnosed with Cancer a Week After Her Honeymoon Helps Others... FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... Cooperativity of BRAF/MAPK Pathway Inhibition and Immune Checkpoint Blockade in Patients... Targeted Drug Combo May Change Care for Rare Brain Tumor Craniopharyngioma
